Results 51 to 60 of about 39,201 (181)

REMDESIVIR y COVID-19 [PDF]

, 2020
Ante la gran cantidad de información circulante respecto a los medicamentos para el tratamiento de COVID-19 y considerando que es necesario ser objetivos respecto a la información fiable y científica disponible referente al medicamento (ifa) REMDESIVIR ...
Manassero, Carlos
core   +1 more source

Safety and effectiveness of remdesivir for the treatment of COVID-19 patients with end-stage renal disease: A retrospective cohort study

Journal of Microbiology, Immunology and Infection
Background: Remdesivir has been used to treat severe coronavirus 2019 (COVID-19); however, its safety and effectiveness in patients remain unclear. This study aimed to investigate the safety and effectiveness of remdesivir in patients with COVID-19 with ...
Yan-Bo Huang, Chip-Jin Ng, Cheng-Hsun Chiu, Chung-Hsien Chaou, Shi-Ying Gao, Shou-Yen Chen   +5 more
doaj   +1 more source

The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis

Case Reports in Infectious Diseases, 2020
Remdesivir is a nucleoside analog prodrug with broad-spectrum antiviral activity, including against coronaviruses. This has prioritized the inclusion of remdesivir in coronavirus disease 2019 (COVID-19) clinical trials.
Vincent Peyko, Helena Ladd, Anthony Cutrona   +2 more
doaj   +1 more source

Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis

Swiss Medical Weekly, 2023
AIMS OF THE STUDY: Remdesivir has shown benefits against COVID-19. However, it remains unclear whether, to what extent, and among whom remdesivir can reduce COVID-19-related mortality. We explored whether the treatment response to remdesivir differed by
Janne Estill, Plamenna Venkova-Marchevska, Huldrych F. Günthard, Sara Botero-Mesa, Amaury Thiabaud, Maroussia Roelens, Laure Vancauwenberghe, Lauro Damonti, Ulrich Heininger, Anne Iten, Peter W. Schreiber, Rami Sommerstein, Sarah Tschudin-Sutter, Nicolas Troillet, Danielle Vuichard-Gysin, Andreas Widmer, Torsten Hothorn, Olivia Keiser   +17 more
doaj   +1 more source

Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential.

PLoS ONE
FDA approved remdesivir, which was though very effective against SARS-corona virus in cell culture system but in human its efficacy was below 10%, as reported. The main reasons are due to the poor stability of remdesivir in presence plasma.
Ashok Chakraborty, Anil Diwan, Vijetha Chiniga, Vinod Arora, Yogesh Thakur, Jayant Tatake, Rajesh Pandey, Preetam Holkar, Neelam Holkar   +8 more
doaj   +1 more source

Persistent SARS‐CoV‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report [PDF]

Respirol Case Rep
This case report presents a 69‐year‐old woman with chronic lymphocytic leukaemia who exhibited prolonged SARS‐CoV‐2 RNA positivity for 127 days despite standard treatments. This case emphasises the profound immunodeficiency in CLL patients and highlights the necessity for tailored therapeutic strategies to manage persistent COVID‐19 infections ...
Khamseh F, Moghtader‐Mojdehi A, Nemati Z, Haghighi M.   +3 more
europepmc   +2 more sources

Hydro‐ and Lipophilicity of Molecular‐Size‐Controlled Hydrogel Drug Carriers

Advanced Materials Technologies, EarlyView.
We investigate nano‐sized hydrogel drug carriers with tailored hydro‐ and lipophilicity. We design their encapsulation and structure‐forming capabilities and follow them in real time during fabrication using time‐resolved and in situ grazing incidence x‐ray scattering.
Elisabeth Erbes, Naireeta Biswas, Calvin J. Gavillet, Matthias Schwartzkopf, Krishnayan Basuroy, Qing Chen, Andrei Chumakov, Susann Frenzke, Marc Gensch, Korneliya Gordeyeva, Patrycja Kielb, Sonja Kirchner, Volker Körstgens, Peter Müller‐Buschbaum, Henrike M. Müller‐Werkmeister, Jan Rubeck, Sreevidya Thekku Veedu, Jose de Jesus Velazquez‐Garcia, Vivian Waclawek, Daniel Söderberg, Stephan V. Roth, Simone Techert   +21 more
wiley   +1 more source

PPA-2021-0023 - Remdesivir Overview

, 2022
By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19.
Sandro G Viveiros Rosa (12694006), Wilson C. Santos (7624058)   +1 more
core   +1 more source

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

Case Reports in Women's Health, 2020
Summary: Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus ...
Jonathon Anderson, Jordan Schauer, Suzanne Bryant, Cornelia R. Graves   +3 more
doaj   +1 more source

Safety and heart rate changes in Covid-19 patients treated with Remdesivir

International Journal of Infectious Diseases, 2021
Objectives: Limited data are available regarding the occurrence and the extent of cardiac rhythm disturbances in patients with COVID-19 treated with Remdesivir.
Natale Daniele Brunetti, MD, PhD, Mariacristina Poliseno, MD, Irene Francesca Bottalico, MD, Antonio Centola, MD, Laura Montemurro, MD, Salvatore Sica, MD, Teresa Santantonio, MD, Sergio Lo Caputo, MD   +7 more
doaj   +1 more source